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Transforming growth factor-b (TGFb) suppresses tumor formation since it inhibits cell growth and
promotes apoptosis. However, in advanced cancers TGFb elicits tumor promoting effects through
its ability to induce epithelial-mesenchymal transition (EMT) which enhances invasiveness and
metastasis; in addition, TGFb exerts tumor promoting effects on non-malignant cells of the tumor,
including suppression of immune surveillance and stimulation of angiogenesis. TGFb promotes EMT
by transcriptional and posttranscriptional regulation of a group of transcription factors that sup-
presses epithelial features, such as expression of components of cell junctions and polarity com-
plexes, and enhances mesenchymal features, such as production of matrix molecules and several
cytokines and growth factors that stimulate cell migration. The EMT program has certain similari-
ties with the stem cell program. Inducers and effectors of EMT are interesting targets for the devel-
opment of improved diagnosis, prognosis and therapy of cancer.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
The transforming growth factor-b (TGFb) family of cytokines has
33 members in humans, including TGFb isoforms, activins, bone
morphogenetic proteins (BMPs), and growth anddifferentiation fac-
tors (GDFs). These factors regulate growth, survival, differentiation
and migration of cells, and have important roles during embryonal
development and in the control of adult tissue homeostasis [1,2].
TGFb family members are implicated in several diseases, including
ﬁbrotic conditions, autoimmune diseases and cancer [3]. During
carcinogenesis, TGFb has a dual role; initially it suppresses tumori-
genesis by inducing growth arrest and promoting apoptosis, how-
ever, in advanced cancers, where TGFb often is overexpressed [4],
it promotes tumorigenesis by induction of epithelial-mesenchymal
transition (EMT), whereby tumor cells become more invasive and
prone to form metastases [5]. The tumor promoting effects of TGFb
also include effects on non-malignant cells of the tumor; thus, TGFb
suppresses immune surveillance, and promotes angiogenesis and
the recruitment of inﬂammatory cells which secrete several cyto-
kines that act on the tumor cells (Fig. 1).
TGFb signals via formation of a heterotetrameric complex of type
I and type II serine/threonine kinase receptors, in which the consti-
tutively active type II receptor phosphorylates and activates the
type I receptor [1,2]. A crucial signaling pathway downstream ofal Societies. Published by Elsevier
).TGFb receptors is composed of transcription factors of the Smad
family (Fig. 2). Receptor-activated Smads (Smad2 and 3 for TGFb)
are phosphorylated in SXS-motives in their C-terminals, whereafter
they form complexes with the common-mediator Smad4. Smad
complexes accumulate in the nucleus where they, in cooperation
with other transcription factors, co-activators and co-repressors,
regulate the transcription of speciﬁc genes (Fig. 2). Smad signaling
is carefully regulated by posttranslational modiﬁcations of Smads
involving activating and inhibitory phosphorylations by different
kinases, and ubiquitination by different ubiquitin ligases that con-
trol stability and activity of Smads. One of the target genes of TGFb
is the Smad7 gene; induction of the inhibitory Smad7 creates a neg-
ative feedback loop which controls TGFb signaling. In addition to
Smad signaling, TGFb induces several other signaling pathways,
e.g. the Erk MAP kinase pathway which is activated via tyrosine
phosphorylation of the adaptor Shc, allowing docking of the Grb2-
Sos1 complex which leads to activation of Ras and the downstream
ErkMAP kinase pathway [6]. In addition, the ubiquitin ligase TRAF6
binds to the TGFb type I receptor and mediates TGFb activation of
the MAP kinase kinase kinase TAK1, the MAP kinase kinase 3/6,
and the Jun/p38 MAP kinases (Fig. 2) [7,8]. TRAF6 also mediates
cleavage of the type I TGFb receptor in amannerwhich is dependent
on themetalloproteinase TACE and protein kinase C (PKC), whereaf-
ter the intracellular part of the receptor is translocated into the nu-
cleus where it induces a transcriptional program promoting cell
invasiveness (Fig. 2) [9]. Additional non-Smad pathways induced
by TGFb include phosphorylation of PAR6 by the TGFb type IIB.V. Open access under CC BY-NC-ND license.
Fig. 1. Actions of TGFb during cancer progression. A growing primary carcinoma along the epithelial layer of an organ is shown on top with the lumen of the organ and the
underlying basement membrane. Round pink cells represent hyperproliferating benign cells. Round red cells represent more advanced carcinoma cells that then undergo EMT
(triangular red cells) and move towards the blood vessel that is surrounded by yellow endothelial cells. Various stromal cell components are represented by elongated beige
(e.g. cancer associated ﬁbroblasts) and polygonal green cells (e.g. macrophages). The bottom part captures an aspect of extravasation and metastatic colonization, with most
cells shown as round red cells, emphasizing MET at the metastatic site. Word captions summarize key events during the progression.
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well as activation of the tyrosine kinase Src, the small GTPase Rho,
and the phosphatidylinositol 30-kinase (PI3-kinase) [1].
TGFb was ﬁrst shown to induce EMT almost 20 years ago [10].
The aim of the present review is to discuss the mechanism where-
by TGFb induces EMT and its role in TGFb-induced invasiveness
and metastasis of tumor cells.
2. Characteristics of EMT
EMT is typically characterized by the loss of cell–cell adhesions
and apical-basal polarity, and the development of a ﬁbroblastoid
motile phenotype. Together with its reversal, mesenchymal-to-epi-
thelial transition (MET), EMT occurs normally during embryonal
development, e.g. in the formation of mesenchyme during gastrula-
tion, in neural crest delamination, in the development of placenta,
somites, heart valves, urogenital tract and secondary palate, as well
as during branching morphogenesis of different organs [5]. EMT is
characterized by loss of epithelial cell-cell contacts by suppressionof components that build up junctional complexes, such as E-cad-
herin, ZO-1, CAR, occludin, claudin-1 and claudin-7 [1]. Cells hereby
become capable of detaching from each other and move away from
the organized epithelial tissue. Cells also lose polarity via loss of
components of polarity complexes, e.g. CRB3 and LGL2. Changes in
microﬁlaments, microtubules and intermediate ﬁlaments further
promote the architectural reorganization and cell motility. In paral-
lel, cells acquire mesenchymal features, such as production of ma-
trix proteins, e.g. ﬁbronectin and collagen, and production of
metalloproteases, which also facilitates cell migration. Finally, a
number of cytokines and growth factors are induced during EMT,
which ampliﬁes the EMT program and promotes cell migration,
including the cytokines TGFb, Wnt, Notch ligands, ILEI (Interleu-
kin-like EMT-inducer), HGF (hepatocyte growth factor), EGF (epi-
dermal growth factor) and PDGF (platelet-derived growth factor).
In addition to EMT, there are also examples of other reprogram-
ming processes, e.g. endothelial-mesenchymal transition (endo-
MT) and the differentiation of epithelial-derived mesenchymal
cells to myoﬁbroblasts (EMyoT).
Fig. 2. TGFb receptor signaling and the EMT program. Two adjacent epithelial cells are shown tethered via: (a) tight junctions made of occludin (occ), claudins (clau) and JAM
proteins that are bound to ZO family proteins that crosslink to the actin ﬁbers (red crossed lines); (b) adherence junctions made of E-cadherin (E-cad) to which is bound b-
catenin (b-cat) and a-catenin (a-cat). Four different scenarios of TGFb receptor tetrameric complexes are shown providing different signaling outputs (from left to right): (i)
TGFb receptor signaling to Smads, with R-Smad phosphorylation followed by complex formation with the Co-Smad, nuclear accumulation of the complex and binding to DNA
(double helix) together with transcription factors (TF). (ii) TGFb receptor signaling to p38 MAPK via poly-ubiquitination (blue circles) of TRAF6 and TAK1, and phosphorylation
of MKK3/6 and p38. Smad7 serves as a platform for the kinases. MAPK signaling feeds to the transcriptional complex made by Smads and TFs. (iii) The TGFb receptor complex
with TRAF6 activates the protease TACE that cleaves the type I receptor and releases its intracellular domain (ICD) that moves to the nucleus and binds to chromatin. These
three signaling pathways regulate transcription of genes leading to downregulation (red small circle) of the epithelial program and upregulation (green small circle) of the
mesenchymal program. (iv) TGFb receptor signaling to the polarity complex via receptors localized at tight junctions, with the type II receptor phosphorylating Par6, leading
to recruitment of the ubiquitin ligase Smurf1 that degrades RhoA. The signaling and junctional complexes are shown in different cells for clarity, but are of course present in
all epithelial cells.
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EMT is promoted by chronic inﬂammation and occurs in con-
junction with tissue ﬁbrosis [11], during which epithelial cells
are converted to myoﬁbroblasts, the latter secreting large amounts
of collagen and other matrix molecules, as revealed by cell tracking
studies [12]. Evidence has been obtained that EMT is important
during CCL4-induced liver ﬁbrosis [13] and TGFb-induced lung
ﬁbrosis [14]. During cardiac [15] and kidney [16] ﬁbrosis, endothe-
lial cells are converted to mesenchymal cells by Endo-MT. The
proﬁbrotic effect of TGFb, e.g. its well-established ability to pro-
mote accumulation of matrix molecules by inducing their synthe-
sis and inhibiting their degradation, reﬂects its EMT promoting
activity.
In several tumor models in animals, it has been demonstrated
that EMT occurs and promotes invasiveness and metastasis. Direct
evidence that EMT is of relevance in human cancers has been more
difﬁcult to obtain, possibly due to the fact that EMT is transient and
reliable markers have been lacking [5]. Evidence supports the no-
tion that tumor invasion may be aided by EMT at the invasive front
of tumors [17], but tumors can also invade their environment on an
EMT-independent manner [18].
Pathological EMT is similar to physiological EMT and involves
similar signaling pathways (see further below).4. Mechanism of TGFb induction of EMT
At the heart of TGFb regulation of EMT is a nuclear reprogram-
ming involving a set of transcription factors, i.e. the basic helix loop
helix proteins Twist and E47, the zinc ﬁnger proteins Snail and Slug(also called Snail2), the zinc ﬁnger and homeodomain proteins
ZEB1 (also called dEF1) and ZEB2 (also called SIP1) [19], and FOXC2
[20]. These factors regulate each other in an elaborate manner
(Fig. 3). Thus, Snail upregulates Slug [21,22] and Twist [23], Snail
and Twist induce ZEB1 [24,25] and Slug [26], and Snail induces
ZEB2 [22]. Together, the factors repress the expression of E-cad-
herin, which is a crucial step of EMT, as well as other epithelial
markers, but also enhance the expression of mesenchymal genes.
As will be discussed below, several pathways induced by TGFb con-
tribute to the regulation of these transcription factors. Moreover,
TGFb cooperates with several other factors such as Notch, Wnt,
integrins and certain tyrosine kinase receptor ligands, in their
regulation.
4.1. Smad signaling is important for TGFb-induced EMT
TGFb-induced activation of Smad complexes has crucial roles
during induction of EMT [27–30]. However, whereas Smad4 and
Smad3 promote EMT, Smad2 inhibits EMT of keratinocytes [31].
Given the important roles of Smad molecules in TGFb-induced
EMT, it is not surprising that mechanisms that affect Smad levels
or activities affect EMT. Thus, ablation of Smad2 in keratinocytes
enhances EMT of keratinocytes [31] and of human renal epithelial
cells [32]. In addition, ubiquitin ligases that promote poly-ubiqui-
tination and proteasomal degradation of Smads, such as WWP2,
have been shown to affect EMT [33]. Moreover, the transcription
intermediary factor 1c (TIF1c), which can ubiquitinate Smad4
[34] or replace Smad4 in a Smad2/3 complex [35], was shown to
suppress TGFb-induced EMT [36].
Smad signaling induces the expression of high mobility group
A2 (HMGA2), a nuclear protein which contains three AT-hooks
Fig. 3. The nuclear program of EMT induced by TGFb stimulation. TGFb signaling is
represented by a box that summarizes the three pathways (i–iii) presented in Fig. 2.
The nuclear program is divided in two parts: (a) Smad, MAPK and TGFb type I
receptor ICD signaling leads to induction of the key transcription factors HMGA2,
Snail, Slug, Twist and ZEB. HMGA2 induces expression of Snail and Twist. Snail
induces expression of Slug, Twist and ZEB. Twist induces expression of Slug and
ZEB. Snail, Slug, Twist and ZEB regulate the expression of genes of the epithelial and
mesenchymal program. Red small circles show negative regulatory connections,
while green small circles show positive regulatory connections. (b) The transcrip-
tional module also induces expression of miR-155 that negatively regulates RhoA;
of miR-491-5 that negatively regulates Par3; of Twist that induces miR-10b, which
negatively regulates the homeobox factor HOXD10; and of ZEB, which transcrip-
tionally represses miR-200 family genes that negatively regulate SIRT1 and ZEB.
Finally, TGFb signaling (extended arrow representing non-Smad signaling pathway)
activates Akt2, which leads to transcriptional repression of the miR-200 family. In
addition, hypoxia is shown to induce HIF-1a, which binds to HDAC3 and leads to
activation of Snail and Twist, in a cooperative manner with TGFb signaling.
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other transcription factors, including Smads. HMGA2 upregulates
Snail [21,22] and Twist [37]. Interestingly, HMGA2 cooperates
with Smads in the induction of Snail in a feed-forward mechanism
(Fig. 3).
4.2. Smads cooperate with other pathways in TGFb-induced EMT
TGFb has been shown to cooperate with oncogenic Ras in the
induction of Snail and promotion of EMT [38]. In Ras-transformed
breast cancer cells, TGFb upregulates the transcription factor ATF3,
which in turn induces Snail, Slug and Twist [39]. Interestingly, the
cooperation between TGFb and Ras is further enhanced by activa-
tion of the transcription factor NF-jB pathway which enhances
Snail expression [40]. The important topic of signaling crosstalk
is revisited in further detail below.
4.3. Non-Smad pathways contribute to TGFb-induced EMT
A non-Smad signaling pathway which may be of importance in
the promotion of EMT is the TRAF6-mediated cleavage of the type I
receptor by the metalloproteinase (MMP) TACE [9]. The intracellu-
lar part of the receptor is translocated into the nucleus where it
drives the expression of genes involved in tumor cell invasiveness,
e.g. the Snail and MMP2 genes (Fig. 2). An interesting possibility,
which remains to be elucidated, is that the intracellular domainof the receptor binds cooperatively with Smad complexes to the
promoters of genes involved in the invasiveness program.
4.4. Epigenetic mechanisms control EMT
TGFb has been shown to induce the DNA methyl-transferase
DNMT1 in a Smad-dependent manner [41], which contributes to
an epigenetic control of EMT. Moreover, posttranslational modiﬁ-
cations of histone 3 regulate conformation of chromatin at speciﬁc
genomic regions and thereby promote EMT; thus, TGFb stimulation
causes a reduction in the heterochromatin mark di-methylation of
Lys9, an increase in the euchromatin mark tri-methylation of Lys4,
and an increase of the transcriptional mark tri-methylation of
Lys36 in histone 3 [42]. These changes depend mainly on lysine-
speciﬁc demethylase-1 (Lsd1), and knock-down of Lsd1 by siRNA
inhibits EMT [42].
A recent interesting study showed how hypoxia can enhance
EMT via an epigenetic mechanism, possibly in cooperation with
TGFb stimulation. Hypoxia causes upregulation of Snail and Twist,
as well as of HIF-1a (Fig. 3). The latter upregulates the histone
deacetylase HDAC3, which deacetylates Lys4 of histone 3, leading
to a repression of epithelial-associated gene chromatin structure,
which, in conjunction with Snail and Twist, lower the expression
of epithelial genes [43]. In parallel, in mesenchymal cells, HDAC3
collaborates with the histone methyltransferase WDR5 which
methylates Lys4 of histone 3, causing enhanced expression of mes-
enchymal genes [43]. Through this dual epigenetic mechanism,
HDAC3 efﬁciently promotes EMT.
Interestingly, Smad3 has been shown to collaborate with an-
other histone deacetylase, i.e. HDAC6, in the induction of EMT
[44]. HDAC6 deacetylates a-tubulin in microtubules and thereby
affects cell motility.
4.5. Loss of polarity is an important part of EMT
TGFb causes loss of polarity of epithelial cells by lowering the
amounts of the Par3 protein, which results in a redistribution of
the Par6-aPKC complex from the plasma membrane to the cyto-
plasm and its subsequent disorganization [45]. In addition, Par6
interacts with the type I TGFb receptor; upon TGFb stimulation
Par6 is phosphorylated by the type II receptor, leading to recruit-
ment of the ubiquitin ligase Smurf1 to the junctional complex
(Fig. 2). Hereby, the GTPase RhoA is targeted for ubiquitination
and proteasomal degradation, which promotes EMT [46]. Another
mechanism whereby TGFb induces loss of polarity is via Twist-
mediated induction of ZEB1 [37], which represses the polarity pro-
tein LGL2 [47].
4.6. miRNAs are involved in TGFb-induced EMT
The levels of transcription factors driving EMT are controlled by
miRNAs (Fig. 3). The miR-200 family (miR-200a, miR-200b, miR-
200c, miR-141 and miR-429) and miR-205 have particularly
important roles since they target ZEB1 and ZEB2 mRNAs [48–51].
TGFb downregulates all ﬁve members of the miR-200 family via
activation of the Akt2 serine/threonine kinase [52], thereby allow-
ing accumulation of ZEB1 and ZEB2. The expression of ZEB2 is fur-
ther regulated by a naturally occurring antisense transcript [53].
Interestingly, ZEB2 binds to the promoters of the miR-200 mem-
bers and represses their expression, thus constituting a double-
negative regulatory loop [48,54]. The miR-200 family also targets
the histone deacetylase SIRT1 which further contributes to EMT
by affecting the epigenetic regulation of EMT genes [55].
TGFb also upregulates certain miRNAs, including miR-155,
which targets RhoA [56]. Together with the Par6 mechanism de-
scribed above, this causes a decrease in RhoA level, which pro-
C.-H. Heldin et al. / FEBS Letters 586 (2012) 1959–1970 1963motes dissolution of tight junctions and loss of polarity. This effect
is enhanced by another miRNA which also is induced by TGFb, i.e.
miR-491-5, which targets the polarity protein Par3 [57]. TGFb also
upregulates miR-10b, via induction of Twist; miR-10b targets
HOXD10 and enhances invasiveness and metastasis of breast can-
cer cells [58].
Several other miRNAs have also been found to be up- or down-
regulated during EMT, suggesting that EMT is controlled by a net-
work of miRNAs; however, their speciﬁc roles to promote or
control TGFb-induced EMT remain to be elucidated.
4.7. TGFb-induced differential splicing promotes EMT
TGFb has been shown to induce alternative splicing in breast
epithelial cells, whereby ﬁbroblast growth factor (FGF) receptors
1, 2 and 3 are converted from the IIIb forms to the IIIc forms
[59]. This causes a switch in ligand binding speciﬁcities from
FGF-7 and FGF-10, to FGF-2 and FGF-4; FGF-2 then cooperates with
TGFb to induce EMT. TGFb affects splicing by ZEB1- and ZEB2-med-
iated downregulation of epithelial splicing regulatory proteins
(ESRPs) [60]. ESRPs also affect the splicing of many other genes
and their downregulation contributes signiﬁcantly to EMT [61,62].
4.8. Regulation of mRNA translation contributes to TGFb-induced EMT
As described above, TGFb stimulation leads to activation of
Akt2, which phosphorylates the ribonucleoprotein E1 (hnRNP1
E1). hnRNP E1 in complex with the elongation factor 1A1 (eEF1A1)
binds to a 33 nucleotide sequence in the 30 untranslated regions of
the mRNAs for the adaptor protein Dab2 and the cytokine ILEI, and
represses their translation; Akt2-mediated phosphorylation of
hnRNP E1 dissociates the complex and allows translation of the
mRNAs [63,64]. The importance of this mechanism for EMT was
further consolidated by the ﬁnding that knock-down of hnRNP
E1 expression enhances EMT and metastasis.5. EMT as a product of crosstalk between signaling pathways
TGFb is a particularly efﬁcient inducer of EMT, but EMT is also
promoted by a number of other factors, including Notch, Wnt, IL-
6 and several tyrosine kinase ligands, such as FGF, EGF, PDGF and
HGF. Interestingly, members of the BMP family instead inhibit
EMT and promote MET, however, this happens in a tissue- or con-
text-dependent manner as explained below. Exactly how all these
factors contribute to EMT remains to be elucidated, however, tyro-
sine kinase receptor-induced activation of the Ras-Erk MAP kinase
pathways is likely to act synergistically with TGFb and to contrib-
ute to multiple aspects of the EMT, including pro-invasive and pro-
metastatic behavior of tumor cells of diverse tissue origins [65].
Moreover, several of these growth factors and cytokines induce
each other, thus amplifying and sustaining the EMT process. In
the following sections we discuss selected examples of crosstalk
between TGFb and other growth factors, focusing on the signaling
mechanisms that mediate such crosstalk. We attempt to empha-
size the context-dependency meaning that sometimes one and
the same growth factor contributes to opposite biological out-
comes (e.g. EMT or MET).5.1. Wnt and TGFb crosstalk
The Wnt pathway is implicated in both developmental and tu-
mor-related EMTs. In invasive breast cancer models, canonical Wnt
signaling involves the mobilization of b-catenin to the nucleus
where it acts as a transcriptional cofactor of TCF (T-cell factor)
[66]. The mechanism whereby this pathway elicits EMT involvesthe sequestration of the kinase GSK-3b by the adaptor protein
Axin2, thus prohibiting the kinase from actively phosphorylating
the transcription factor Snail and causing its degradation. This
leads to Snail stabilization, allowing cooperation between Snail
and TCF in promoting the EMT phenotype [66]. Interestingly, the
basic b-catenin/TCF or LEF (lymphoid enhancer factor) signaling
module is often usurped by TGFb signaling in several tissues to eli-
cit EMT, presumably without any direct involvement of Wnt li-
gands. Accordingly, developmental EMT that forms the palate
under the signaling activity of TGFb3 involves direct association
of the Smad complex with LEF1, which represses E-cadherin gene
expression [67]. Thus, TGFb signaling induces expression of Snail
and Wnt signaling stabilizes Snail; since Smads can bind to both
LEF1 and Snail [68], it is possible that during Wnt and TGFb-in-
duced EMT, a common Smad-LEF-Snail complex forms to promote
EMT.
During pulmonary ﬁbrosis, lung epithelial cells exhibit a cell
surface receptor complex between TGFb receptors, integrin recep-
tor a3b1 and E-cadherin, which allows the formation of signaling
complexes between Smads and b-catenin that promote EMT [69].
The Smad/b-catenin complex induced by TGFb in lung epithelial
cells, together with the co-activator p300, also induce the mesen-
chymal a-smooth muscle actin gene [70].
TGFb also induces the expression of the homeobox transcription
factor CUTL1, which then induces the expression of the ligand
Wnt-5A, activating canonical Wnt signaling and promoting EMT
in pancreatic carcinomas [71]. In addition to canonical Wnt signal-
ing, TGFb can induce and cooperate with non-canonical Wnt sig-
naling and together these three signaling pathways form a
network that promotes EMT in mammary cells [72]. The regulated
secretion of extracellular antagonists of both TGFb/activin andWnt
ligands help maintain the epithelial phenotype by protecting the
mammary cell from being exposed to autocrine TGFb or Wnt sig-
nals. When the EMT process starts by pathological exposure to
high levels of these ligands, the extracellular inhibitors become
downregulated, leading to sustained autocrine responses to TGFb
and Wnt, promoting the development of transitory mesenchymal
cells with tumor-initiating capacities (see also next section).
5.2. Notch and TGFb crosstalk
The Notch pathway that speciﬁes cell fate determination during
development crosstalks signiﬁcantly with the TGFb pathway [73].
Notch catalyzes EMT during organogenesis, such as heart valve for-
mation and during oncogenesis [74]. The primordial cells that form
the heart valves are produced via an Endo-MT during which Notch
signaling induces expression and secretion of TGFb, which then in-
duces Snail expression and downregulation of vascular-endothelial
(VE) cadherin. In the same biological system, Notch signaling leads
to Slug expression, whereas Snail expression requires the concerted
action of Notch and TGFb [75]. Interestingly, Notch and TGFb coop-
erate with BMP2 in the induction of Endo-MT in the endocardial tis-
sue [76]. BMP2, similar toWnt, inhibits GSK3b activity, thus leading
to Snail stabilization. Thus, EMT driven by Snail requires both tran-
scriptional induction of its gene, e.g. via TGFb signaling, but also
additional stabilization of the protein via Wnt or BMP signaling,
depending on the cell type that undergoes the transition.
In cultured cell models of EMT, such as human HaCaT keratino-
cytes, human kidney epithelial HK-2 cells and mouse NMuMG
mammary epithelial cells, TGFb signaling, via Smads, leads to
expression of several Notch receptor ligands, including Jagged1
[77–79]. Jagged1 then induces paracrine signaling of the Notch
pathway so that effective epithelial cell cycle arrest and EMT can
take place. Interestingly, genome-wide screens for genes regulated
by TGFb and Notch, demonstrated that a large cohort of genes are
co-regulated by the action of these two pathways. This mechanism
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case of a subset of renal cancer where the TGFb/Notch pathway sig-
nature provides a tool useful for theprognosis of disease progression
[80].
Moreover, Notch signaling induces secretion of TGFb, as shown in
lung epithelial cells undergoing EMT and terminal myoﬁbroblast dif-
ferentiation [81]. An important marker of myoﬁbroblast differentia-
tion, a-smooth muscle actin, is induced in the lung cells in response
to Notch activation in a TGFb- and Smad3-dependent manner, while
the Jagged1 ligand is also induced so that a sustained Notch pathway
activity can be elicited. On the other hand, in different cell types, such
as esophageal epithelial cells that develop squamous carcinomas,
Notch signaling by the Notch3 receptor counteracts EMT by affecting
the balance of the miR-200/ZEB/TGFb axis described above, and thus
promoting epithelial differentiation [82].
5.3. PDGF and TGFb crosstalk
The importance of oncogenic Ras and TGFb signaling for EMT
and metastasis has been summarized above. The studies on the
Ras-TGFb crosstalk also revealed that an important factor induced
after TGFb signaling is PDGF that acts in a sequential auto- or par-
acrine manner to promote the sustained EMT and cancer cell inva-
siveness, as ﬁrst demonstrated in liver cancer cells [83]. In fact,
both PDGF-A and the a- and b-receptors are transcriptionally in-
duced by TGFb signaling in Ras-transformed hepatocarcinomas.
In this tumor type, activation of PDGF signaling after prolonged
TGFb exposure leads to additional intracellular signaling via the
PI3K and b-catenin routes that enhance carcinoma survival and
invasiveness [84]. In addition, the paracrine action of the TGFb-in-
duced PDGF was shown to target stromal myoﬁbroblasts, which
support the invasive phenotype of the hepatocarcinomas [85].
The input of TGFb signaling on PDGF secretion and PDGFR expres-
sion may not be direct, as recent analysis of the TGFb–PDGF cross-
talk in hepatocarcinomas and in lung carcinomas revealed that the
TGFb-inducible secretion of ILEI (see above for mechanism) is an
important mediator of PDGF secretion and PDGF receptor expres-
sion, which then lead to signaling via b-catenin and Stat3 to estab-
lish EMT [86]. The TGFb–PDGF crosstalk mechanism was also
established in metastatic breast cancer cells, whereby both PDGF
a- and b-receptors were upregulated in response to TGFb, and
the resulting PDGF signals contributed to EMT and invasive growth
by stimulation of several downstream pathways including the
Stat1 pathway [87].
The extensive crosstalk between multiple signaling pathways in
the induction of EMT indicate that efﬁcient inhibition of EMT dur-
ing tumor progression using pharmacological agents, may need to
involve the targeting of cooperating signaling pathways
simultaneously.
6. Links between EMT and tumor-initiating cells
Over the past few years, a new concept of cancer progression
has been explored. It emphasizes the importance of a relatively
rare cancer cell type with properties similar to stem cells, that con-
tributes to the growth, expansion and dissemination of the tumor
and also to its relative resistance to chemotherapy [88]. In refer-
ence to this rare cell type, we use the term tumor-initiating cell
(TIC) instead of cancer stem cell, since it is unlikely that cancer
cells can fully de-differentiate to generate genuine stem cells that
can then repopulate and reconstitute a normal tissue, organ or a
complete organism. The cellular and molecular features of TICs
and cancer cells undergoing EMT show interesting similarities.
Thus, transcription factors of the EMT program, such as Snail and
Twist, but also cytokines that promote EMT, such as TGFb, promotethe generation and survival of TICs [72,89,90]. A prominent cell
type with potential to promote tumorigenesis and assist tumor
cells to undergo the transition towards metastasis, are mesenchy-
mal stem cells (MSCs). It is therefore interesting that overexpres-
sion of Snail or Twist in breast cancer cells produces cancer cell
phenotypes with common molecular and behavioral features with
the MSCs [91]. We explained above how Snail and Twist expression
is controlled by growth factor pathways, including TGFb. Under
in vitro culture conditions of normal fetal liver cells, TGFb signaling
leads to Snail induction and EMT that produces mesenchymal cells
with progenitor-like phenotypic features [92]. Furthermore, TGFb
and Wnt signaling contribute to the emergence and survival of
mesenchymal cells with progenitor-like phenotype and enhanced
tumorigenic potential from breast cancer cells [72]. Moreover,
TGFb and tumor necrosis factor-a (TNFa) induce EMT and genera-
tion of TICs of breast cancer cells that exhibit resistance to anti-
cancer drugs [93]. The mesenchymal cells produced via EMT lack
their tight junctions, as explained above, and exhibit low levels
of expression of proteins that assemble the tight junction, such
as the claudins. In particular, claudin 3, 4 and 7 are downregulated
in breast cancer EMT and this phenotype is now used for the clas-
siﬁcation of a subtype of breast cancers as ‘‘claudin-low’’ [93].
In addition to the similarities between EMT and the generation of
TICs, there are similarities between MET and the generation of in-
duced pluripotent stem cells (iPSCs) from somatic cells, such as
ﬁbroblasts. Themolecular process that induces the epithelial pheno-
type during the generation of iPSCs is controlled by the embryonic
stem cell transcription factors Oct4, Sox2, Klf4 and the proto-onco-
protein c-Myc. Oct4 and Sox2 bind to and repress the Snail gene
expression, Klf4 induces expression of E-cadherin driving the
epithelial differentiation of iPSCs, and the proto-oncogene c-Myc re-
presses the genes encoding TGFb and the type II TGFb receptor [94].
It should be pointed out that all studies so far that link the pro-
cess of EMT with TICs in human and experimental cancers rely on
in vitro culture protocols of tumor cells and their genetic or growth
factor-mediated manipulation. The relevance of these ﬁndings for
the actual tumors in patients requires further research. At the
molecular level, we need to understand how pathways like TGFb
and transcription factors like Snail change the phenotype of tumor
cells leading to the generation of TICs.
7. Importance of TGFb-induced EMT in metastasis
Since metastasis is the foremost cause of cancer lethality, a dee-
per understanding of the mechanisms that promote metastasis is
needed [95]. TGFb signaling has been linked to the process of
metastasis in various cancer types, including breast and lung
[95,96]. Current evidence supports the notion that EMT facilitates
invasiveness and intravasation into lymph or blood vessels of can-
cer cells as one of the early manifestations of metastasis [5]. In
addition to the direct effects of EMT on cancer cells, invasive tumor
cells that have undergone EMT secrete many growth factors and
chemokines that stimulate and recruit stromal cells, facilitating
migration and intravasation of the tumor cell [95,97]. From a TGFb
perspective, it is important to elucidate whether TGFb, in addition
to the induction of EMT that initiates the cascade towards metas-
tasis, continues to have active roles during additional steps in the
trajectory that guides tumor cells to form metastases.
7.1. The dual role of TGFb in cancer progression and its links to EMT as
established in mouse cancer models
A suppressive role of TGFb1 on breast epithelial growth in vivo
emerged from early studies of transgenic mice expressing an ac-
tive, mature TGFb1 transgene in the mammary gland [98]. Under
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partially the development of the female mammary duct due to
hypoproliferation of epithelial cells. When the TGFb1 mouse was
crossed with an oncogenic mouse expressing the EGF family recep-
tor Neu/Erb2 in the breast, the primary breast tumors developed
equally well as the tumors induced by the Neu oncogene alone,
demonstrating that the oncogene acted dominantly over the anti-
proliferative TGFb1 [99]. Surprisingly, the Neu/TGFb1 mice showed
increased numbers of circulating tumor cells and lung metastases,
while the tumor cells expressed protein markers that supported
the presence of EMT and enhanced invasive capacity, corroborating
the established model that EGF/Ras and TGFb signaling synergisti-
cally enhance EMT. The pro-metastatic effect of TGFb1 in breast
cancer was further demonstrated by an inducible TGFb1 transgene
expressed together with the polyomavirus middle T antigen that
primed oncogenesis in the breast, leading to accelerated lung
metastasis in a doxycycline-dependent manner [100]. Parallel
studies using TGFb receptor transgenes provided additional and
mechanistically detailed evidence for the dual response of breast
cancer to TGFb signaling [101]. A constitutively active point mu-
tant type I TGFb receptor expressed in the breast together with
the Neu oncogene delayed the onset of primary breast cancer,
but eventually, when the tumors grew, it enhanced the rate of lung
metastasis. In contrast, a dominant negative, deletion mutant type
II TGFb receptor accelerated the onset of primary tumor growth,
but also reduced the rate of lung metastasis [101]. Knockout of
the TGFb type II receptor in the mammary epithelium led to hyper-
plasia in the mammary gland of the normal mouse consistent with
a growth inhibitory action of TGFb in normal epithelial biogenesis
[102]. However, crossing of the TGFb type II deﬁcient mouse with a
mouse expressing the oncogenic polyoma middle T antigen in its
breast, caused a more rapid onset of primary tumor growth, but,
in contrast to the ﬁndings of Siegel and colleagues [101], it in-
creased lung metastases [102]. The reason for the apparent dis-
crepancy between the two studies [101,102] is not known.
The above studies in the breast are supported by analogous
studies in the skin. Targeted expression of TGFb1 in keratinocytes
followed by a chemical carcinogenesis protocol, showed a reduced
number of benign primary skin lesions, but eventually, as carcino-
genesis progressed, TGFb1 induced a higher rate of malignant tu-
mors with spindle-like carcinoma cells, thus providing one of the
ﬁrst demonstrations of TGFb-induced EMT in vivo [103]. The same
result was reached by an inducible TGFb1 transgene in the skin and
chemical carcinogenesis, showing that when TGFb1 was induced
early it could suppress tumor growth, whereas when TGFb1 was
induced at the papilloma stage, it actually promoted invasive tu-
mor growth and metastasis [104]. The metastatic spindle cells
exhibited strong signs of EMT in this model as well. Interestingly,
co-expression of the TGFb1 transgene and the dominant negative
TGFb type II receptor mutant in keratinocytes resulted in loss of
the EMT response, as judged by epithelial and mesenchymal pro-
tein marker analysis in the growing tumors; however, the primary
tumor cells that expressed epithelial proteins (e.g. E-cadherin)
were able to invade and metastasize with an even higher rate
[105]. The loss of EMT was correlated with decreased activation
of Smad signaling, whereas the enhanced invasiveness and metas-
tasis correlated with enhanced non-Smad (Rho/Rac GTPase and Erk
MAPK) signaling.
Transgenic mice expressing the dominant negative mutant type
II receptor of TGFb in basal and follicular skin cells showed unper-
turbed normal tissue homeostasis [106]. Upon chemical carcino-
genic challenge of these mice, the skin cells hyperproliferated
and developed a higher number of faster growing carcinomas, sup-
porting a tumor suppressor action of TGFb in the skin. In a parallel
model, combination of oncogenic K- or H-Ras expression with
knockout of the TGFb type II receptor in epithelial skin cells ofthe head and neck, led to dramatic tumor growth and metastasis,
associated with enhanced endogenous TGFb1 production [107].
The reason why loss of the TGFb type II receptor from skin cells
does not perturb normal tissue homeostasis is due to a compensa-
tion of the enhanced hyperproliferation of the skin cells by an en-
hanced apoptosis [108]. In the same skin type II receptor knockout
model, spontaneous squamous carcinomas were observed in the
rectum and genitals since the epithelial cells of these organs prolif-
erate constantly during adult life. When the loss of the type II
receptor was combined with an oncogenic Ras mutation, tumori-
genesis was accelerated and the affected keratinocytes exhibited
enhanced invasiveness [108]. The skin studies in mice nicely reca-
pitulate the ﬁndings from human cancer patients with skin hyper-
plasias and head-and-neck cancer [107,108].
7.2. The tumor cell environment is important for TGFb promotion of
tumor progression
The above example of skin carcinogenesis suggests that cancer
cell autonomous TGFb signaling is responsible for the EMT; how-
ever, carcinoma-derived TGFb may act also on other cell types in
the tumor environment to elicit invasiveness and metastasis. This
has indeed been ﬁrmly proven in breast, skin, prostate and stom-
ach cancer mouse models. Fibroblast-speciﬁc knockout of the TGFb
type II receptor led to increased numbers of stromal cells and en-
hanced hyperplasia of the adjacent epithelium in the prostate
and stomach [109], possibly by increased production of HGF by
the ﬁbroblasts, acting on the epithelial cells. It is noteworthy, that
HGF, also known as scatter factor, was the ﬁrst growth factor
linked with the process of EMT [110]. According to this mouse
model, the tumor suppressor action of TGFb is elicited by signaling
in tumor stromal ﬁbroblasts and not by signaling in the carcinoma
cells. A similar action of TGFb was observed in breast cancer, by
xenografting breast cancer cells into the same ﬁbroblast-speciﬁc
TGFb type II receptor knockout mouse [111]. Primary breast cancer
growth and lung metastasis were enhanced, and correlated with
overproduction of HGF and its receptor c-Met and enhanced sig-
naling via Stat3 and Erk MAPK in the carcinoma cells. In addition,
the enhanced lung metastasis in mice with conditional deletion
of the TGFb type II receptor in breast cancers driven by the poly-
oma middle T antigen, as described above, was shown to be facil-
itated by myeloid cells of the Gr-1+CD11b+ phenotype [112]. The
myeloid cells inﬁltrated the invasive front of the breast carcinoma
by responding to the chemokines SDF-1 and CXCL5 via their corre-
sponding receptors CXCR4 and CXCR2, and led to enhanced pro-
duction of TGFb1 and metalloproteinase activity that promoted
invasiveness and metastasis. In this breast cancer model, the pri-
mary tumor stroma underwent signiﬁcant alterations that corre-
lated with increased primary tumor size; the importance of a
tumor suppressor action of TGFb, acting at the level of tumor initi-
ation, progression and metastasis, was conﬁrmed once again [113].
The link between tumor-derived TGFb and various chemokines of
the CXCL family that mediate the communication between carci-
noma cells and their stromal neighbors in breast cancer has also
been veriﬁed in human cancer samples using mRNA expression
and statistical correlation analyses [114].
7.3. The pro-metastatic actions of TGFb include EMT but also other
processes critical for metastasis
The central link between TGFb signaling, EMT and metastasis
was pioneered by studies using the mouse breast cancer cell model
EpRas that overexpressed the H-Ras oncogene [115,116].
Engineering the dominant negative TGFb type II receptor mutant
into these cells was shown to block normal cell-autonomous TGFb
signaling, inhibit EMT, delay primary tumor growth in xenografted
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These studies established a central role of TGFb in every step of can-
cer progression and a strong correlation between EMT and meta-
static potential. In addition, the EpRas model demonstrated the
need of crosstalk between TGFb signaling and Ras-mediated Erk/
MAPK and PI3-kinase signaling in order to elicit both EMT and
metastasis [116,117]. In this model, TGFb induces the secretion of
the cytokine ILEI, whose action is critical for metastasis [118]. In
agreement with the necessity of crosstalk between TGFb and Ras
signaling, ILEI leads to downstream signalingmediated by secretion
of PDGF and consecutive Stat3 activation, which function indepen-
dent of the TGFb pathway to drive EMT and metastasis in a model
of hepatocellular carcinoma [86]. Thus, in these models, TGFb acts
by inducing ILEI and then ILEI takes over by inducing PDGF signaling
towards EMT and metastasis.
Similar to the EpRas cell model, hepatocarcinoma cells were
shown to undergo EMT in response to TGFb by inducing expression
of the CXCR4 receptor, which endowed them with responsiveness
to SDF-1a, thus promoting survival necessary for efﬁcient invasive-
ness [119]. EMT has also been described in studies of invasive met-
astatic myeloma, where it was shown to be driven by the concerted
action of multiple growth factors, including TGFb, EGF and HGF
[120]. These growth factors are secreted by myeloid-derived sup-
pressor cells that inﬁltrate the growing tumor by responding to
chemotactic recruitment mediated by the chemokine CXCL5 that
is secreted by the myeloma cells and acting on the suppressor cells
found within the bone marrow.
In addition to the sequential waves of growth factor, cytokine
and chemokine secretion induced by TGFb, additional regulators
are involved in metastasis. Some of these regulators control both
EMT and invasiveness, whereas others affect only late stages of
metastasis, and possibly act only at the distant site of secondary tu-
mor growth during colonization. In invasive breast cancers of the
basal-like subtype, high expression of annexinA1 has been recorded
[121]. Annexin A1 acts as a positive regulator of TGFb signaling and
promotes EMT and invasiveness; its downregulation using RNAi
blocks lung metastases. A mechanistically interesting link between
TGFb-driven EMTand the onset ofmetastasis has been illustrated by
studies of breast cancer cells growing in three-dimensional organo-
typic cultures and the regulation of E-cadherin expression in re-
sponse to TGFb [122]. Downregulation of E-cadherin prepares
cancer cells for invasiveness by allowing a switch in the expression
pattern of speciﬁc integrin receptors; induction of integrin b1 plays
a critical role in invasiveness and metastasis.
Studies of breast cancer cell invasion in host mice using intravi-
tal imaging technology permitted the observation of two types of
tumor cell motility [123]. Single-cell motility was shown to be dri-
ven by active response to TGFb found in the tumor microenviron-
ment, involvement of several signaling mediators such as Smad4
and Rho GTPases, and directional movement towards blood ves-
sels. While this type of migration was fully blocked by inhibitors
of TGFb receptor kinases, the tumor cells continued their invasive
behavior even in the presence of the TGFb inhibitor, based on the
second type of motility that involved cohorts of cells that migrated
primarily towards the lymphatic vessels instead of blood vessels.
Based on this study, metastatic dissemination of breast cancer to
the lung requires transient TGFb signaling, and involves solitary
invasive cells that presumably have undergone EMT, which metas-
tasize using blood but not lymphatic vessels [124]. An important
target of TGFb signaling that participates in lung metastasis of
breast cancer cells is the angiopoietin-like 4, a direct gene target
of Smad signaling [125]. While TGFb induces angiopoietin-like 4
expression at the primary tumor prior to metastasis, the functional
role of this secreted protein is elicited only later during metastatic
colonization, as the angiopoietin-like 4 protein assists during the
process of extravasation by opening the strongly adhering endo-thelial cells in capillary vessels of the lung, thus facilitating the
deposition of tumor cells to the metastatic site.
In contrast to the studies on breast cancer metastasis to lung
that emphasizes transient TGFb signaling, additional studies of
breast cancer metastasis to bone concluded that TGFb signaling
is important both during the early phase of metastasis and during
the colonization in the bone, where TGFb derived from the bone
storages after the destructive action of osteoclasts could assist in
the survival of the metastatic cells in the new niche [126,127].
These ﬁndings using modern non-invasive imaging technology
conﬁrm earlier pioneering studies of breast cancer metastasis to
bone, which identiﬁed that TGFb acts at the osteolytic metastatic
site, where it induces expression of the cytokine interleukin-11
(IL-11) and the pro-angiogenic growth factor connective tissue
growth factor (CTGF), affecting the action of osteoclasts and angi-
ogenesis at the new metastatic lesion [128]. Consequently, abroga-
tion of TGFb signaling in the primary breast cancer cells by means
of silencing the Smad4 gene, prior to metastatic spread in the host
mouse, was detrimental to the metastatic colonization and inhib-
ited the critical responses of IL-11 and CTGF [27,129]. These genet-
ic experiments highlight the possible relevance of using TGFb
inhibitors to prevent EMT and cancer metastasis.
7.4. Can TGFb inhibitors be used as anti-metastatic agents with clinical
efﬁcacy?
The strong evidence for pro-tumorigenic and pro-metastatic ac-
tions of TGFb, suggests that inhibitors of this signaling pathway
may be useful to treat advanced cancer [130,131]. Whereas the tu-
mor suppressor action of TGFb complicates the use of TGFb inhib-
itors for cancer treatment, pre-clinical studies using anti-TGFb
inhibitors show some promising results.
The Fc:TGFb type II receptor fusion protein acts as a decoy for all
isoforms of TGFb; administration of this TGFb inhibitor intrave-
nously in the polyoma middle T antigen transgenic breast cancer
model, had no impact on primary tumor growth but effectively re-
duced breast cancer invasiveness and lung metastases [132]. Sim-
ilar anti-metastatic efﬁcacy was found when this inhibitor was
used in syngeneic xenograft breast cancer models of 4T1 and
EMT-6 cells that metastasize to lungs [132]. Moreover, expression
of the decoy protein as a transgene in the mammary gland of mice
[133] and crossing with the Neu breast oncomouse or injecting iso-
genic melanoma cells in the tail vein, effectively reduced lung
metastases in all cases. Similar results were obtained by a neutral-
izing pan-TGFb antibody when administered systemically to the
polyoma middle T antigen breast cancer model followed by ioniz-
ing radiation or doxorubicin therapy [134]. The anti-TGFb antibody
blocked lung metastasis and normalized the adverse effects of ion-
izing radiation and doxorubicin, as both of these therapeutic
modalities enhanced secretion of TGFb by tumor cells. A second
study with the anti-TGFbmonoclonal antibody 1D11 and the xeno-
graft metastasis model of 4T1 breast cancer cells, demonstrated
strong efﬁcacy against lung metastasis [135].
In addition to direct inhibition of the TGFb ligand, interference
with factors that assist TGFb signaling speciﬁcally during cancer
metastasis may be an alternative and more targeted method of
therapy. Two recent studies highlight this possibility. Studies of
EMT and metastasis by lung cancer cells in response to TGFb
uncovered a role of the transcription factor peroxisome prolifera-
tor-activated receptor c (PPARc) as an inhibitor of Smad3 tran-
scriptional function during EMT and metastasis [136]. Natural
ligands of the PPARc protein such as troglitazone and rosiglitazone
activate PPARc, which then blocks Smad3 function and thus effec-
tively inhibit EMT in vitro and metastasis in xenografted mice in
vivo. Moreover, the transmembrane protein Klotho that is mainly
expressed by kidney cells can be shed, and this secreted form binds
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to the natural TGFb ligand [137]. Klotho can therefore act as a TGFb
inhibitor and administration of Klotho was effective against metas-
tasis in a xenograft mouse model [137]. Klotho does not show
speciﬁcity for the TGFb receptor and is also known to block Wnt
and IGF signaling.
Finally, low molecular weight inhibitors that inactivate the
TGFb receptor kinases have been developed [130]. A dual type II
and type I receptor kinase inhibitor, LY2109761, gave impressive
inhibition of metastasis in an orthotopic pancreatic cancer model
[138]. A comparative study that examined breast cancer metastasis
to lung or bone after treatment with the anti-TGFb 1D11 antibody
and the receptor kinase inhibitor LY2109761 concluded that both
agents were equally efﬁcient to inhibit metastasis [139]. The
anti-TGFb therapy was equally effective in lung or bone metastasis
and the inhibitor blocked both metastatic angiogenesis in the lung
and osteoclastic activity in the bone lesions. A recent study has
examined the well-established phenomenon of acquired drug
resistance to inhibitors of signaling molecules in cancer, now
focusing on the TGFb receptor inhibitor LY2109761 [140]. Effects
of chronic administration of the inhibitor in mice with skin cancer
caused by tumor cell transplantation or chemical carcinogenesis
were analyzed; the study revealed for the ﬁrst time development
of drug-resistant tumors with signs of EMT and aggressive inva-
siveness. Thus, the use of the new generation anti-TGFb signaling
agents progresses with caution and the results of the ongoing clin-
ical trials by Eli Lilly are awaited with great anticipation. It is pos-
sible that such anti-TGFb drugs may be used against metastasis
only for certain tumors, in limited doses, and in combination with
other inhibitors that target more selectively EMT or the following
metastatic cascade.
8. Future perspectives
The role of TGFb in EMT, carcinoma invasiveness and metastasis
to multiple organs has been ﬁrmly established based on in vitro
and in vivo studies. Remaining open challenges are the elucidation
of the comprehensive network of molecules that initiate and exe-
cute the EMT program. Identiﬁcation of key enzymes within this
network will be critical from a therapeutic perspective. Further-
more, the link between mechanisms that elicit TGFb-induced
EMT and mechanisms that maintain cancer stem cells in different
organs is just emerging and awaits long series of investigations. Fi-
nally, the precise role of EMT in the multi-stage metastatic process
of human cancer needs to be clariﬁed. Such studies will involve
analyses of tumor tissues and blood samples with circulating tu-
mor cells with regard to expression and activation of the networks
of proteins that participate in the EMT program.
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